http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
CytoSorbents Announces the REFRESH 2-AKI Trial Data Monitoring Committee Has Recommended Study Resumption Following Favorable Review of Safety Data
-
CytoSorbents to Report Q2 2020 Operating and Financial Results
-
Cytosorbents (CTSO) Provides Q2 Financial Results, Corporate Update
-
CytoSorbents Provides Preliminary Q2 2020 Financial Results and Corporate Update
-
CytoSorbents to Host Key Opinion Leader Call on the Use of CytoSorb Blood Purification to Remove Antithrombotic Medications in Patients at Risk of Bleeding
-
/C O R R E C T I O N -- CytoSorbents Corporation/
-
Cytosorbents (CTSO) Announces Commercial Launch and Immediate Availability of CytoSorb To Treat Cytokine Storm In Many Latin American Countries
-
CytoSorbents Announces Commercial Launch and Immediate Availability of CytoSorb To Treat Cytokine Storm In Many Latin American Countries As COVID-19 Cases Rise
-
CytoSorbents Awarded $2,897,172 Phase III STTR Contract to Advance HemoDefend-BGA Plasma and Whole Blood Filter to Clinical Trials
-
CytoSorbents Announces Virtual Annual Meeting
-
CytoSorb® is E.U. Approved to Remove Rivaroxaban, a Leading Factor Xa Inhibitor and Novel Oral Anticoagulant, During On-Pump Cardiothoracic Surgery
-
CytoSorbents Reports First Quarter 2020 Financial and Operational Results
-
CytoSorbents Promotes Vincent J. Capponi to President
-
CytoSorbents Receives $1.1 Million in Non-Dilutive Funding from the New Jersey Business Tax Certificate Transfer Program
-
CytoSorbents to Report Q1 2020 Operating and Financial Results
-
Cytosorbents Appoints Dr. Efthymios N. Deliargyris, M.D., As Chief Medical Officer
-
Cytosorbents (CTSO) Announces FDA Grants Breakthrough Designation to CytoSorb for Removal of Ticagrelor During Cardiopulmonary Bypass in Emergent and Urgent Cardiothoracic Surgery
-
Development Update: U.S. FDA Grants Breakthrough Designation to CytoSorb for Removal of Ticagrelor During Cardiopulmonary Bypass in Emergent and Urgent Cardiothoracic Surgery
-
Cytosorbents (CTSO) Says New Study Suggests CytoSorb Improves Clinical Outcomes in Pneumonia Patients With Septic Shock and ARDS on ECMO
-
New Study Suggests CytoSorb Improves Clinical Outcomes in Pneumonia Patients With Septic Shock and Acute Respiratory Distress Syndrome (ARDS) on ECMO
-
Cytosorbents (CTSO) Announces U.S. FDA Grants it Emergency Use Authorization for Use in Patients with COVID-19 Infection
-
U.S. FDA Grants CytoSorb® Emergency Use Authorization for Use in Patients with COVID-19 Infection
-
Cytosorbents (CTSO) CEO to Discuss COVID-19 Pandemic and its CytoSorb Treatment of Cytokine Storm
-
CytoSorbents CEO to Discuss COVID-19 Pandemic and its CytoSorb® Treatment of Cytokine Storm in Cowen COVID-19 Series Conference Call Today
-
CytoSorb® Receives Marketing Approval in Mexico with Commercialization to Commence with Partner Fresenius Medical Care
-
Cytosorbents (CTSO) Announces CytoSorb Used to Treat More than 70 Critically-Ill COVID-19 Patients and Specifically Added to Coronavirus Treatment Guidelines in Italy and Panama
-
CytoSorb® Used to Treat More than 70 Critically-Ill COVID-19 Patients and Specifically Added to Coronavirus Treatment Guidelines in Italy and Panama
-
Cytosorbents (CTSO) Provides Update on CytoSorb and COVID-19 Coronavirus Activities
-
CytoSorbents Provides Update on CytoSorb and COVID-19 Coronavirus Activities
-
CytoSorbents Announces 2019 Financial and Operational Results
-
CytoSorbents Highlights Recent Publication Using CytoSorb during Cardiac Surgery for Infective Endocarditits
-
CytoSorb Shipment Arrives in Designated Mainland China Hospitals to Treat Cytokine Storm in Critically-ill Patients with COVID-19 Coronavirus Infection
-
CytoSorbents to Report Fiscal 2019 Operating and Financial Results and to Present at Cowen 40th Annual Healthcare Conference
-
CytoSorbents Enters Agreement with China Medical System Holdings Limited to Bring CytoSorb to Mainland China to Treat Critically-ill Patients with COVID-19 Coronavirus Infection
-
Cytosorbents (CTSO) Announces CytoSorb is Approved, Available for Removal of Ticagrelor During Cardiopulmonary Bypass in E.U.
-
CytoSorb® is Approved and Available for the Removal of Ticagrelor, a Leading Anti-Platelet Drug, During Cardiopulmonary Bypass in the E.U.
-
Cytosorbents (CTSO) Says CytoSorb Could Be Used for Coronavirus
-
CytoSorb, the Wuhan Coronavirus, and Cytokine Storm
-
Cytosorbents (CTSO) Treatment Improves Rat Survival Following Lethal Intravenous Dose of Fungal Aflatoxin
-
CytoSorb Treatment Improves Rat Survival Following Lethal Intravenous Dose of Fungal Aflatoxin
-
Cytosorbents (CTSO) Reports Preliminary 2019 Financial Results, Issues Stockholder Letter
-
CytoSorbents Reports Preliminary 2019 Financial Results and Issues Stockholder Letter
-
CytoSorbents to Present at Biotech Showcase™ 2020
-
CytoSorbents to Present at the Piper Jaffray 31st Annual Healthcare Conference
-
Cytosorbents (CTSO) temporarily pauses enrollment of its REFRESH 2-AKI study at the recommendation of DMC
-
CytoSorbents Changes Contract Research Organizations and Temporarily Pauses Enrollment in REFRESH 2-AKI Study
-
CytoSorbents to Present at the Three Part Advisors 2019 Southwest IDEAS Investor Conference
-
Dr. Eric Mortensen to Leave CytoSorbents At Year End
-
CytoSorbents Reports Third Quarter 2019 Financial Results
-
CytoSorbents Announces Additions to its International Clinical Team

